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Coronary stenting
has become a mainstay of 
interventional cardiology.
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Stent evolution
The rate of stent thrombosis are increased with both PES 
and SES compared with their bare metal counterpart, a 
difference that emerges <1 year after stent implantation.
Stone GW N Engl J Med 2007
Late stent thrombosis, defined as any platelet rich thrombus occupaying
>25% of lumen >30 days after DES implantation.
Finn AV et al, ATVB 2007
DES – Stent Thrombosis
2Acquired platelet activation following stent implantation is well
documented* and may affect both short- and long-term outcomes
in patients treated with stents.
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*By means of platelet aggregation measurement as well as by surface receptor expression
in circulating blood
PCI and platelet activation Stent Thrombosis
• Prevention is currently based upon the 
combination of aspirin (75-325 mg/day) plus 
clopidogrel (600 mg loading dose followed 
by 75 mg/day). 
• revention is currently based upon the 
co bination of as iri (75-325 g/day) plus 
cl i rel (600 g loading dose follo ed 
by 75 g/day). 
 No data are available on platelet
behaviour after stopping thienopyridine 
treatment.
DES, platelet activation and drug treatement
•During dual antiplatelet therapy TF-
positive platelets are significantly 
higher than in medically treated 
medically treated (MT) patients. 
•TF-positive platelets further increase 
at T1 and T2 (ASA only ) remaining 
significantly higher than those of MT 
patients.
Platelet TF in DES treated patients – 10° GSP
3Of the 48 patients enrolled, 16 (33%) 
underwent a de novo PCI on another
coronary lesion over a 3 year period of
time.
Follow up of DES–treated patients Patients who underwent a new PCI within
three years (   ) had TF levels in resting platelets
significantly higher than patients 
who were event-free (   )
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Camera et al, submitted
Patients with the TF positive platelet value at one month after 
clopidogrel withdrawal above the median had higher risk to undergo a 
new PCI within three years (RR=1.5 for 10 points % increase).
Patients’ stratification according to the TF positive platelet 
value 30 days after clopidogrel withdrawal
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Months
• Carotid Artery Stenting (CAS) is an evolving method 
to treat carotid stenosis. 
• Platelet activation in CAS occurs as a result of vessel 
wall damage and subendothelium exposure. 
• The dual antiplatelet regimen has a significant impact 
on reducing adverse neurological outcomes. 
No data on platelet activation during dual 
antiantiplatelet therapy and after thienopyridine 
discontinuation have been examined in CAS.
Carotid artery stenting
4To compare platelet activation in patients who underwent
carotid revascularization (n=38) versus stable angina 
patients who underwent coronary revascularization
(n=16) with bare metal stent (BMS) implantation.
Study Aim & Design
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Platelet activation markers:
•GPIIb/IIIa activated complex (PAC1) 
•P-Selectin (CD62P)
•Tissue Factor (TF)
•Percentage of total monocyte-platelet aggregates
•Percentage of TF-positive monocyte-platelet aggregates
were assessed by whole blood flow cytometry in resting
conditions and after in vitro ADP stimulation (10 µM, 15 min).
Methods
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5Platelet Tissue Factor expression during DAT
– ADP-stimulated
P<0.0001
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Platelet activation markers during ASA
– Resting conditions
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6Total
TF positive 
aggregates
Monocyte-platelet aggregates
– Resting conditions
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• Significant higher levels of TF-positive platelets and TF-
positive MPA were observed in peripheral blood of coronary 
patients who underwent revascularization with BMS 
implantation compared to patients with carotid artery stenting, 
both 1 month after stenting and 1 months after thienopyridine 
discontinuation. 
• This prothrombotic platelet phenotype may have implications 
for thrombotic complication in coronary patients.
Conclusions
